ClinicalTrials.gg
RecruitingNCT06384924Updated May 7, 2026

Raman Spectroscopy and Skin Cancer

An observational study in Skin Cancer, Basal Cell Carcinoma and Squamous Cell Carcinoma, sponsored by Tiezhi Zhang. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Primary conditionCarcinoma, Basal CellRegistry: Skin NeoplasmsReclassifiedWhy we changed it
Registry
Skin Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Basal Cell
Why
  1. The study's listed conditions name Carcinoma, Basal Cell, a narrower term within Skin Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tiezhi Zhang · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Planned enrollment
22nd of 26
20 · median 80
Started
2025
with 8 others
Observational
27 of 171
2 open now
Primary completion
2027-02
later than 11 of 37 live
Registered
147th of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 22nd largest by planned enrollment of the 26 observational ones that give a count, is one of 9 that started in 2025, is one of 27 observational ones, reaches primary completion later than 11 of the 37 other live ones, and was the 147th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to find out if Raman Spectroscopy, a type of imaging, can be used to determine the size of skin cancer tumors. The main question it aims to answer is:

-Can Raman Spectroscopy help figure out how far a tumor spreads?

This study will take measurements using laser light from an experimental, handheld probe by lightly touching the skin.

Read the detailed description

Radiation therapy is an alternative to surgery for localized tumors with excellent tumor control and cosmetic outcome. Raman Spectroscopy has potential to be a useful non-invasive, non-destructive, real-time, in-vivo tool for differentiation of cancerous vs. non-cancerous tissues. With this knowledge and future studies, this will ultimately guide skin brachytherapy more accurately and avoid unnecessary radiation to cosmetically and functionally important tissues including eyelid, nose, lips or skin folds.

The purpose of this study is to determine the feasibility of Raman Spectroscopy to identify microscopic infiltration extent of skin cancer beyond grossly visible tumor, using artificial intelligence methods of supervised and un-supervised machine learning algorithms, including pattern recognition, convolutional neural networks, k-means clustering and principal component analysis.

03

Conditions studied

  • Skin Cancer
  • Basal Cell Carcinoma
  • Squamous Cell Carcinoma

Browse trials for

04

In context

Carcinoma, Basal Cell Reclassified

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

This study's planned enrollment of 20 is below the median of 142 across 95 observational studies indexed under Carcinoma, Basal Cell.

Browse Carcinoma, Basal Cell studies →

Lead sponsor

This is the only study on the registry with Tiezhi Zhang as lead sponsor.

Compared within Carcinoma, Basal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population will include patients with confirmed skin cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed skin cancer (either basal cell carcinoma or squamous cell carcinoma)
  • Participants must plan to receive brachytherapy treatment for the skin cancer at the study site.
  • Ability to provide consent to the study.

Exclusion criteria

Exclusion Criteria:

  • Patient belongs to a vulnerable population (Minors (under 18 years old), Adults unable to consent, prisoners).
  • Lesions on the eyelid or in close proximity to the eye
  • Pregnant women, or women of childbearing age who refuse pregnancy testing.
  • Patient has pacemaker.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Raman Spectroscopy

    Device: Raman Spectroscopy handheld probe (EmVision, FL, USA) · Device: Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA)

Interventions

  • DeviceRaman Spectroscopy handheld probe (EmVision, FL, USA)

    The probe is approximately the size of a pen or pencil. The handheld probe is connected to the laser source using a cable. The probe is placed in light contact with the skin. The features of the laser light after it bounces off the skin is collected. This measurement can allow us to see tissue characteristics. This is a single session that will take approximately 15 minutes.

  • DeviceRaman Spectroscopy laser source (Hubner Photonics Inc, CA, USA)

    This light source will create the laser light that will pass through the cable and through the handheld probe onto the skin.

07

What researchers measure

Primary outcomes

  1. Feasibility of Raman Spectroscopy to observe differences in Raman spectra between visible lesion, skin surrounding lesion and contralateral normal skin.

    Collect the Raman spectroscopy data starting from the center of visible lesion moving outward and also contralateral normal skin. Observe the different spectra peak wavelengths and intensities, which correspond to different chemical composition of the tissue. The Raman Spectra has units of wavelength Raman shift (1/centimeter) on the horizontal axis and arbitrary units of intensity on the vertical axis.

    Time frame: 1 year

Secondary outcomes

  1. Compare the size of clinically defined margin and Raman-defined margin

    After generating a sufficient model for predicting cancerous from non-cancerous tissue based on Raman spectra, compare the volume of the clinically defined margin (uniform 1-2 centimeter margin upon clinical discretion) to the Raman-defined margin. The Raman-defined margin will not be used for treatment. The volume is measured in cc (cubic centimeter).

    Time frame: 1 year

  2. Compare the dose delivered to surrounding critical structures when using clinically defined margin and Raman-defined margin

    Radiation dose to the critical structures (e.g., eyes) from the plan using clinically defined margin (uniform 1-2 centimeter margin upon clinical discretion) will be collected. A second plan (not to be used for treatment) will be generated based on the Raman-defined margin. The dose to critical structures will be compared for both plans. The unit for dose will be centiGray (cGy).

    Time frame: 1 year

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 40 observational studies under Carcinoma, Basal Cell, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 75. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Feb 13, 2025
Primary completionEst.
Feb 13, 2027
CompletionEst.
Feb 13, 2027
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06384924
Lead sponsor
Tiezhi Zhang
Responsible party
Tiezhi Zhang (Medical Physicist, Clinical Assistant Professor, Stony Brook University) — Sponsor-investigator
First posted
Apr 25, 2024
Start date
Feb 13, 2025
Primary completion
Feb 13, 2027 (estimated)
Completion
Feb 13, 2027 (estimated)
Last update
May 7, 2026

Study contacts

Tiezhi Zhang
Contact
tiezhi.zhang@stonybrookmedicine.edu
631-444-3617
Tiezhi Zhang
principal investigator · Stony Brook Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion